These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

769 related items for PubMed ID: 9613778

  • 21. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
    Schütt P, Passon J, Ebeling P, Welt A, Müller S, Metz K, Moritz T, Seeber S, Nowrousian MR.
    Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
    [Abstract] [Full Text] [Related]

  • 22. Prospective randomized clinical trial comparing high-dose ifosfamide + GM-CSF vs high-dose cyclophosphamide + GM-CSF for blood progenitor cell mobilization.
    Vela-Ojeda J, Tripp-Villanueva F, Montiel-Cervantes L, Sánchez-Cortés E, Ayala-Sánchez M, Guevara-Moreno ME, García-León LD, Rosas-Cabral A, Esparza MA, González-Llaven J.
    Bone Marrow Transplant; 2000 Jun; 25(11):1141-6. PubMed ID: 10849526
    [Abstract] [Full Text] [Related]

  • 23. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
    Nademanee A, Sniecinski I, Schmidt GM, Dagis AC, O'Donnell MR, Snyder DS, Parker PM, Stein AS, Smith EP, Molina A.
    J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609
    [Abstract] [Full Text] [Related]

  • 24. ESHAP and G-CSF is a superior blood stem cell mobilizing regimen compared to cyclophosphamide 1.5 g m(-2) and G-CSF for pre-treated lymphoma patients: a matched pairs analysis of 78 patients.
    Watts MJ, Ings SJ, Leverett D, MacMillan A, Devereux S, Goldstone AH, Linch DC.
    Br J Cancer; 2000 Jan; 82(2):278-82. PubMed ID: 10646877
    [Abstract] [Full Text] [Related]

  • 25. CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients.
    Todisco E, Castagna L, Sarina B, Mazza R, Magagnoli M, Balzarotti M, Nozza A, Siracusano L, Timofeeva I, Anastasia A, Demarco M, Santoro A.
    Eur J Haematol; 2007 Feb; 78(2):111-6. PubMed ID: 17313558
    [Abstract] [Full Text] [Related]

  • 26. Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patients (>/=60 years) with non-Hodgkin's lymphoma: comparison with patients <60 years treated within the same protocol.
    Jantunen E, Mahlamäki E, Nousiainen T.
    Bone Marrow Transplant; 2000 Oct; 26(7):737-41. PubMed ID: 11042654
    [Abstract] [Full Text] [Related]

  • 27. Peripheral blood progenitor cell collection without close monitoring of peripheral blood CD34+ cells: A feasible strategy for multiple myeloma or pre-treated Non-Hodgkin's Lymphoma patients mobilized with low-dose cyclophosphamide plus G-CSF.
    Callera F, Cavenaghi L, de Melo CM.
    Transfus Apher Sci; 2009 Apr; 40(2):91-5. PubMed ID: 19233728
    [Abstract] [Full Text] [Related]

  • 28. Ifosfamide and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma.
    Mayer J, Korístek Z, Vásová I, Vorlícek J, Vodvárka P.
    Bone Marrow Transplant; 1999 Mar; 23(5):413-9. PubMed ID: 10100553
    [Abstract] [Full Text] [Related]

  • 29. Mobilization kinetics of peripheral blood progenitor cells after IAPVP-16 salvage chemotherapy plus G-CSF in lymphoproliferative disorders.
    Altés A, López R, Martino R, Martinez C, Cabezudo E, Muñoz L, Santamaría A, Perea G, Briones J, Salar A, Sureda A, Brunet S, Madoz P, Sierra J.
    Bone Marrow Transplant; 2000 Jul; 26(2):127-32. PubMed ID: 10918421
    [Abstract] [Full Text] [Related]

  • 30. Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies.
    Clavio M, Garrone A, Pierri I, Michelis GL, Balocco M, Albarello A, Varaldo R, Canepa P, Miglino M, Ballerini F, Canepa L, Gobbi M.
    Oncol Rep; 2005 Oct; 14(4):933-40. PubMed ID: 16142354
    [Abstract] [Full Text] [Related]

  • 31. Superior autologous blood stem cell mobilization from dose-intensive cyclophosphamide, etoposide, cisplatin plus G-CSF than from less intensive chemotherapy regimens.
    Stewart DA, Guo D, Morris D, Poon MC, Ruether BA, Jones AR, Klassen J, Auer I, Luider J, Chaudhry A, Brown C, Russell JA.
    Bone Marrow Transplant; 1999 Jan; 23(2):111-7. PubMed ID: 10197794
    [Abstract] [Full Text] [Related]

  • 32. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients.
    Zinzani PL, Tani M, Molinari AL, Stefoni V, Zuffa E, Alinari L, Gabriele A, Bonifazi F, Salvucci M, Tura S, Baccarani M.
    Haematologica; 2002 Aug; 87(8):816-21. PubMed ID: 12161357
    [Abstract] [Full Text] [Related]

  • 33. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study.
    Kleiner S, Kirsch A, Schwaner I, Kingreen D, Schwella N, Huhn D, Siegert W.
    Bone Marrow Transplant; 1997 Dec; 20(11):953-9. PubMed ID: 9422474
    [Abstract] [Full Text] [Related]

  • 34. ESHAP + fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result of 127 patients.
    Akhtar S, Tbakhi A, Humaidan H, El Weshi A, Rahal M, Maghfoor I.
    Bone Marrow Transplant; 2006 Feb; 37(3):277-82. PubMed ID: 16400345
    [Abstract] [Full Text] [Related]

  • 35. Clonogenic potential and phenotypic analysis of CD34+ cells mobilized by different chemotherapy regimens.
    Cesana C, Regazzi E, Garau D, Caramatti C, Mangoni L, Rizzoli V.
    Haematologica; 1999 Sep; 84(9):771-8. PubMed ID: 10477448
    [Abstract] [Full Text] [Related]

  • 36. High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization.
    Tarella C, Di Nicola M, Caracciolo D, Zallio F, Cuttica A, Omedè P, Bondesan P, Magni M, Matteucci P, Gallamini A, Pileri A, Gianni AM.
    Bone Marrow Transplant; 2002 Dec; 30(11):725-32. PubMed ID: 12439694
    [Abstract] [Full Text] [Related]

  • 37. Comparison of peripheral blood progenitor cell yield from standard chemotherapy used in the treatment of lymphoid malignancies and high-dose cyclophosphamide: a retrospective review of 141 patients.
    Assouline S, Sylvestre MP, Carriere P, Shustik C, Laneuville P.
    Transfusion; 2006 Feb; 46(2):174-9. PubMed ID: 16441591
    [Abstract] [Full Text] [Related]

  • 38. Ifosfamide in combination with paclitaxel or doxorubicin: regimens which effectively mobilize peripheral blood progenitor cells while demonstrating anti-tumor activity in patients with metastatic breast cancer.
    Prince HM, Gardyn J, Millward MJ, Rischin D, Francis P, Gates P, Chapple P, Quinn M, Juneja S, Wolf M, Januszewicz EH, Richardson G, Scarlett J, Briggs P, Brettell M, Toner GC.
    Bone Marrow Transplant; 1999 Mar; 23(5):427-35. PubMed ID: 10100555
    [Abstract] [Full Text] [Related]

  • 39. G-CSF primed peripheral blood progenitor cells in autologous bone marrow transplantation: parameters affecting bone marrow engraftment.
    Bolwell BJ, Fishleder A, Andresen SW, Lichtin AE, Koo A, Yanssens T, Burwell R, Baucco P, Green R.
    Bone Marrow Transplant; 1993 Dec; 12(6):609-14. PubMed ID: 7511016
    [Abstract] [Full Text] [Related]

  • 40. Efficient peripheral blood stem cell mobilization with low-dose G-CSF (50 microg/m2) after salvage chemotherapy for lymphoma.
    Martínez C, Sureda A, Martino R, Cancelas JA, Madoz P, García J, Brunet S.
    Bone Marrow Transplant; 1997 Nov; 20(10):855-8. PubMed ID: 9404926
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 39.